Eclipse 3d version 13

The prescribed dose was 50 Gy in 25 fractions over the entire breast or the chest wall, and on the lymph nodes (level L4 + internal mammary nodes (IMN) +/− L3, L2 and L1). A boost from 10 to 16 Gy on the tumor base could also be applied in accordance with institutional recommendations.
All the planning scans were taken from the tragus to the intervertebral foramen L2/L3, without the injection of a contrast agent, using a Toshiba Aquilion LB scanner (Toshiba Corp., Minato, Japan). The width of the sections was 3 mm.
The patients were placed on their back using the AIO positioning system (ORFIT, Wijnegem, Belgium) on a surface at a 5° angle. Their arms were placed above the head, and an immobilization system was placed under the knees.
The scanner images were transferred to a contouring software (Eclipse 3D version 13.6; Varian Medical Systems Inc., Palo Alto, CA, USA). Target volume delineation was performed in accordance with the ESTRO recommendations in force [1 (link)].
The anatomic humeral heads were delineated on simulation scanners in the treatment position.
The contoured images were then transferred to the tomotherapy machine’s planning system (TomoTherapy Hi-ART version 3.1.2.3; Tomotherapy Inc., Madison, WI, USA).

CT sections were transferred to the contouring system (Eclipse 3D version 13.6; Varian Medical Systems Inc., Palo Alto, USA). The breast/chest wall and lymph node clinical target volumes (CTV) were delineated according to our guidelines then ESTRO guidelines after the official publication [34 (link)]. The primary tumour bed was contoured according to previously described methods [35 (link)]. A 5 mm expansion around the CTV was performed to define the planning target volume (PTV). The PTV was cropped 3 mm under the skin.